Blood
Articles in this Issue
Autologous stem cell transplantation and real-world outcomes in angioimmunoblastic T-cell lymphoma: A national cohort study
Abstract Background The benefit of high-dose chemotherapy and autologous stem cell transplantation (ASCT) as a consolidation strategy after i...
Clinical outcomes and safety of tislelizumab maintenance therapy following autologous stem cell transplantation in patients with relapsed or refractory diffuse large b-cell lymphoma
Abstract Objective: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma, and patients with relapsed/refr...
CaDAnCe-104, an ongoing, open-label, phase 1b/2 master protocol study of Bruton tyrosine kinase degrader BGB-16673 in combination with other agents in patients with relapsed/refractory B-cell malignancies
Abstract Introduction: Bruton tyrosine kinase (BTK) inhibitors are effective in B-cell malignancies. Despite this, most patients experience...
Risk of second primary malignancy following chimeric antigen receptor T-cell therapy: A real-world cohort study
Abstract Background: Chimeric Antigen Receptor T-cell (CAR-T) therapy has significantly improved outcomes in relapsed or...
Hypogammaglobulinemia in CLL: Analysis of clinical and laboratory correlates
Abstract Background: Hypogammaglobulinemia is commonly noted in chronic lymphocytic leukemia (CLL) patients, predisposing patients to infect...
Blinatumomab mitigates the impact of traditional adverse prognosticators among children with standard risk b-acute lymphoblastic leukemia: Updated results of the Children's oncology group (COG) Trial AALL1731
Abstract COG study AALL1731 established that adding two cycles of the bispecific T-cell engager blinatumomab to risk-adapted chemotherapy (c...
Babesia induced cytokine storm: A rare cause of secondary hemophagocytic lymphohistiocytosis
Abstract Background: Hemophagocytic Lymphohistiocytosis (HLH) is characterized by overactivation of cytotoxic T lymphocytes, natural killer...
Impact of TBI, donor age, and transplant era on outcomes of allogeneic transplantation in acute lymphoblastic leukemia: Evidence from 748 patients in Latin America
Abstract Introduction: Allogeneic hematopoietic stem-cell transplantation (HCT) remains a key component of consolidation therapy for many ad...
Beyond remission: Sexual health and quality of life in survivors of acute leukemia
Abstract Introduction: Although treatment for acute leukemias is typically intensive and prolonged, advances in therapy have significantly i...
The phases of hematology-oncology fellowship: A single site qualitative Study
Abstract Background: Medical training consists of stepwise transitions to new and progressively specialized roles (e.g., medical student to...
Efficacy and safety of vipor (P) in relapsed or refractory large B-cell lymphoma
Abstract Background Relapsed and refractory large B-cell lymphomas (r/r LBCL) remain a therapeutic challenge, particularly after CAR-T cell t...
Low dose weekly HMA-venetoclax dosing is associated with greater cost-effective efficacy than standard dosing in AML/MDS: Real-world evidence
Abstract Introduction Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) in elderly patients unfit for intensive chemotherapy...
Identification of CD4+ T cells targeting DM-sensitive antigens presented on mismatched HLA-DP alleles, as mediators of a selective graft-versus-leukemia effect.
Abstract Introduction: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) enables hematopoietic reconstitution through donor ste...
CD34+/TNC ratio predicts relapse in AML/MDS patients receiving peripheral blood matched allogeneic stem cell transplantation with post-transplant cyclophosphamide
Abstract Introduction. Allogeneic hematopoietic stem cell transplant (SCT) is an effective treatment for hematologic malignancies. The engra...
A randomized placebo-controlled Phase 1 trial in healthy volunteers investigating safety, pharmacokinetics and pharmacodynamics of a novel menin inhibitor, balomenib (ZE63-0302): Interim analysis.
Abstract Background. MLL/KMT2A rearranged (KMT2Ar) and Mutant NPM1 AML which expresses a cytosolic restricted NPM1 protein (NPM1c) are drive...
All-trans retinoic acid and RARβ agonists enhance the efficacy of IMiD-based treatments for t(4;14) multiple myeloma
Abstract The t(4;14) (p16;q32) translocation stands as a formidable high-risk cytogenetic aberration in patients with multiple myeloma (MM)....
Safety and efficacy of talquetamab + teclistamab in patients with Relapsed/Refractory multiple myeloma from Phase 1b of redirectt-1: Results with an extended median follow-up of 3 years
Abstract Introduction: Talquetamab (Tal, anti-GPRC5D×CD3) and teclistamab (Tec, anti-BCMA×CD3) are the first bispecific antibodies (BsAbs) a...
A phase II study of eltrombopag in patients with low-risk MDS and CMML harboring TET2 mutations
Abstract Study Rationale. TET2 is one of the most commonly mutated genes in clonal hematopoiesis and myeloid malignancies, including low-ris...
Specific environmental factors are associated with increased rates of invasive mucormycosis infections in patients with acute leukemia and myelodysplastic syndrome
Abstract Introduction Climate change has significant impacts on fungal disease, including geographic expansion of endemic mycoses and emergen...
Performance of different large language models (LLMs) as decision support tools across various hematologic malignancies
Abstract Background: In an evolving field with rapid changes in standard of care therapies, second opinions and multidisciplinary review (MD...
An essential link between pyrimidine synthesis and ferroptosis suppression in erythroid differentiation
Abstract The human body produces 2-3 million red blood cells per second. Excessive death of erythroid precursors results in ineffective eryt...
Major adverse cardiovascular events (MACE) in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: A target trial emulation study
Abstract Background: Since tyrosine kinase inhibitors (TKIs) have transformed chronic myeloid leukemia (CML) into a chronic disease with nea...
DNMT3B functions as tumor suppressor in mantle cell lymphoma
Abstract DNA methyltransferases (DNMTs) are an evolutionarily conserved family of DNA methylases responsible for establishing and maintainin...
A real-world analysis of safety and outcomes with first line nivolumab in combination with doxorubicin, vinblastine, and dacarbazine (NAVD) in patients with classic Hodgkin lymphoma (cHL) – a multicenter cohort study
Abstract Introduction: NAVD has become a standard-of-care for frontline (1L) treatment (tx) of advanced stage cHL, based...
Smart start with tislelizumab as frontline treatment in advanced-stage classical Hodgkin lymphoma：a PET-adapted, chemotherapy-sparing phase 2 study
Abstract Background Around 10-30% of classical Hodgkin's lymphoma(cHL) will relapse or refract after treatment with traditional cytotoxic dru...